

Julien Cherfils-Vicini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1347365/publications.pdf>

Version: 2024-02-01

21
papers

1,927
citations

623734

14
h-index

677142

22
g-index

25
all docs

25
docs citations

25
times ranked

3524
citing authors

#	ARTICLE	IF	CITATIONS
1	A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy. <i>Nature Communications</i> , 2021, 12, 653.	12.8	48
2	Neutrophils: mediating TelOxidation and senescence. <i>EMBO Journal</i> , 2021, 40, e108164.	7.8	11
3	A Novel Screen for Expression Regulators of the Telomeric Protein TRF2 Identified Small Molecules That Impair TRF2 Dependent Immunosuppression and Tumor Growth. <i>Cancers</i> , 2021, 13, 2998.	3.7	8
4	Association of TRF2 expression and myeloid-derived suppressor cells infiltration with clinical outcome of patients with cutaneous melanoma. <i>Oncolmmunology</i> , 2021, 10, 1901446.	4.6	2
5	TRF2 positively regulates SULF2 expression increasing VEGF-A release and activity in tumor microenvironment. <i>Nucleic Acids Research</i> , 2019, 47, 3365-3382.	14.5	34
6	Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein <scp>TRF</scp> 2. <i>EMBO Journal</i> , 2019, 38, .	7.8	49
7	Inhibiting <scp>TRF</scp> 1 upstream signaling pathways to target telomeres in cancer cells. <i>EMBO Molecular Medicine</i> , 2019, 11, e10845.	6.9	10
8	Nitric Oxide Synthase 2 Improves Proliferation and Glycolysis of Peripheral Î³ T Cells. <i>PLoS ONE</i> , 2016, 11, e0165639.	2.5	11
9	TRF2-Mediated Control of Telomere DNA Topology as a Mechanism for Chromosome-End Protection. <i>Molecular Cell</i> , 2016, 61, 274-286.	9.7	124
10	Abstract 3230: The role of TRF2 on tumor progression in non-small cell lung cancer: potential modulating effect on myeloid cells. , 2016, , .		0
11	Genetic and Pharmacological Inactivation of the Purinergic P2RX7 Receptor Dampens Inflammation but Increases Tumor Incidence in a Mouse Model of Colitis-Associated Cancer. <i>Cancer Research</i> , 2015, 75, 835-845.	0.9	96
12	A novel pathway links telomeres to NK-cell activity. <i>Oncolmmunology</i> , 2014, 3, e27358.	4.6	8
13	The Wilmsâ€™ tumour suppressor Wt1 is a major regulator of tumour angiogenesis and progression. <i>Nature Communications</i> , 2014, 5, 5852.	12.8	82
14	TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Nonâ€™Small Cell Lung Cancer. <i>Cancer Research</i> , 2014, 74, 5008-5018.	0.9	83
15	The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. <i>Nature Immunology</i> , 2014, 15, 749-757.	14.5	484
16	TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. <i>Nature Cell Biology</i> , 2013, 15, 818-828.	10.3	99
17	Tumor microenvironment is multifaceted. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 13-25.	5.9	95
18	Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma. <i>Cancer Research</i> , 2011, 71, 5412-5422.	0.9	404

#	ARTICLE	IF	CITATIONS
19	Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. <i>Journal of Clinical Investigation</i> , 2010, 120, 1285-1297.	8.2	191
20	Characterization of immune functions in TRAF4-deficient mice. <i>Immunology</i> , 2008, 124, 562-574.	4.4	25
21	NKG2C is a major triggering receptor involved in the V α 1 T cell-mediated cytotoxicity against HIV-infected CD4 T cells. <i>Aids</i> , 2008, 22, 217-226.	2.2	56